Long‐term outcomes following proton therapy for pediatric spinal low‐grade glioma

Abstract Background Due to its rarity, no standard treatment guidelines exist for pediatric spinal low‐grade glioma (LGG‐S). Proton therapy (PT) offers an attractive modality to minimize toxicity. Herein, we present the first published series of pediatric patients who received PT for progressive LGG‐S. Procedures We identified eight consecutive patients with nonmetastatic LGG‐S treated with PT. Cumulative incidence method was used to estimate local control (LC), freedom from distant metastases (FFDM), and freedom from progression (FFP). The Kaplan–Meier product limit method assessed overall survival (OS). Toxicity was assessed according to the Common Terminology Criteria for Adverse Events Version 5.0. Results Median age at diagnosis was 4 years. All patients underwent attempted resection and developed recurrence/progression prior to referral for PT, with median duration between initial surgery and PT of 4.4 years. Median age at the start of PT was 8 years. Most patients ( n = 5) received PT as ≥third line treatment. Seven patients were treated with PT to the primary tumor. Most patients ( n = 7) received between 45–50.4 CGE. Median follow up was 7.8 years. The 10‐year estimates for LC, FFDM, FFP, and OS were 85, 88, 73, and 55%, respectively. One patient experienced malignant transformation and two developed pseudoprogression following PT. No pulmonary, gastrointestinal, or musculoskeletal toxicities were observed during or after PT. Conclusions Despite negative selection bias our experience suggests PT for pediatric LGG‐S offers long‐term disease control with limited toxicity. The favorable therapeutic ratio of PT suggests it should be considered among first‐line therapy in children with nonmetastatic, unresectable LGG‐S.